Panels and models for accurate prediction of tumor mutation burden in tumor samples

Abstract Immune checkpoint blockade (ICB) is becoming standard-of-care in many types of human malignancies, but patient selection is still imperfect. Tumor mutation burden (TMB) is being evaluated as a biomarker for ICB in clinical trials, but most of the sequencing panels used to estimate it are in...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Elizabeth Martínez-Pérez, Miguel Angel Molina-Vila, Cristina Marino-Buslje
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2021
Materias:
Acceso en línea:https://doaj.org/article/1b76c4e637d44f018df09d860ec13ed7
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares